Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3
Lexaria Bioscience Corp. (LEXX)
Company Research
Source: Accesswire
Possible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side EffectsKELOWNA, BC / ACCESSWIRE / July 21, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results.This study demonstrated that DehydraTECHTM enabled colchicine, the latest of several drugs Lexaria has successfully tested with known SARS-CoV-2 antiviral properties, benefited from our proprietary formulation and processing, resulting in increased delivery:DrugCmax* % Improvement(ng/mL)Control(ng/mL)AUClast** % Improvement(hr·ng/mL)Control(hr·ng/mL)Colchicine31.9791%(p=0.0005)16.73104.43167%(p=0.0028)38.97Colchicine is an approved therapeutic with anti-inflammatory effects that is principally used to treat gout and conditions such as cardiac inflammation (i.e., pericarditis), and also has potent effects in mitigati
Show less
Read more
Impact Snapshot
Event Time:
LEXX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEXX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEXX alerts
High impacting Lexaria Bioscience Corp. news events
Weekly update
A roundup of the hottest topics
LEXX
News
- Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study [Yahoo! Finance]Yahoo! Finance
- Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 StudyAccesswire
- Lexaria Awarded New Patents [Yahoo! Finance]Yahoo! Finance
- Lexaria Awarded New PatentsAccesswire
- Lexaria to Present at The LD Micro Invitational XIV [Yahoo! Finance]Yahoo! Finance
LEXX
Analyst Actions
- 3/5/24 - Maxim Group
LEXX
Sec Filings
- 4/9/24 - Form 10-Q
- 3/21/24 - Form 8-K
- 3/21/24 - Form EFFECT
- LEXX's page on the SEC website